This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
Baidoun F, Chen D, Patnaik M, Gangat N, Begna K, Elliott M, et al. Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. Leuk Lymphoma. 2019;60:2483–7.
Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, et al. Myelodysplastic syndrome, unclassifiable (MDS-U) with 1% blasts is a distinct subgroup of MDS-U with a poor prognosis. Am J Clin Pathol. 2017;148:49–57.
Knipp S, Strupp C, Gattermann N, Hildebrandt B, Schapira M, Giagounidis A, et al. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome. Leuk Res. 2008;32:33–7.
de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62.
Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, et al. Allogeneic stem cell transplantation for myelodysplastic syndrome patients with a 5q deletion. Biol Blood Marrow Transplant. 2018;24:507–13.
Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N, et al. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): characteristics of refined MDS types. Leuk Res. 2017;57:78–84.
Carré M, Porcher R, Finke J, Ehninger G, Koster L, Beelen D, et al. Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant: a retrospective study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2020;26:451–7.
Shimoni A, Robin M, Iacobelli S, Beelen D, Mufti GJ, Ciceri F, et al. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the Chronic Malignancies Working Party of the EBMT. Br J Haematol. 2021;195:417–28.
Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017;52:209–15.
Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, et al. Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. Haematologica. 2019;104:929–36.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19.
Acknowledgements
We are indebted to all centres participating to the EBMT database, and especially the ones who contributed to this retrospective analysis.
Author information
Authors and Affiliations
Contributions
JDS, LG, NK, MR, DL, NZ, and IYA were involved in study design, analysis and drafting the paper. All other co-authors contributed data to the study, critically revised the paper and approved the submitted and final version.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Drozd-Sokolowska, J., Gras, L., Zinger, N. et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant 58, 222–225 (2023). https://doi.org/10.1038/s41409-022-01870-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-022-01870-9